SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    The Non-Hodgkin's Lymphoma Pathologic Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer. 1982; 49: 21122135.
  • 2
    Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 13611392.
  • 3
    Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies: report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997. Mod Pathol. 2000; 13: 193207.
  • 4
    Burkitt D. Long-term remissions following one and two-dose chemotherapy for African lymphoma. Cancer. 1967; 20: 756759.
  • 5
    Ostronoff M, Soussain C, Zambon E, et al. Burkitt's lymphoma in adults: a retrospective study of 46 cases. Nouv Rev Fr Hematol. 1992; 34: 389397.
  • 6
    Straus DJ. Treatment of Burkitt's lymphoma in HIV-positive patients. Biomed Pharmacother. 1996; 50: 447450.
  • 7
    Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997; 336: 16411648.
  • 8
    Levine AM, Wernz JC, Kaplan L, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA. 1991; 266: 8488.
  • 9
    Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996; 14: 925934.
  • 10
    Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002; 13: 12641274.
  • 11
    Carbone A, Gloghini A, Gaidano G, et al. AIDS-related Burkitt's lymphoma. Morphologic and immunophenotypic study of biopsy specimens. Am J Clin Pathol. 1995; 103: 561567.
  • 12
    Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood. 1992; 80: 820.
  • 13
    Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet. 1991; 337: 805809.
  • 14
    Spina M, Tirelli U, Zagonel V, et al. Burkitt's lymphoma in adults with and without human immunodeficiency virus infection: a single-institution clinicopathologic study of 75 patients. Cancer. 1998; 82: 766774.
  • 15
    Davi F, Delecluse HJ, Guiet P, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group. J Clin Oncol. 1998; 16: 37883795.
  • 16
    Gill PS, Levine AM, Krailo M, et al. AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol. 1987; 5: 13221328.
  • 17
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 49904997.
  • 18
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 19
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163170.
  • 20
    Rosner B. Hypothesis testing: categorical data. In: RosnerB. Fundamentals of biostatistics. Belmont, CA: Wadsworth Publishing Co., 1994: 345442.
  • 21
    Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting–Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17: 38353849.
  • 22
    Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971; 31: 18601861.
  • 23
    Rodriguez V, Cabanillas F, Burgess MA, et al. Combination chemotherapy (“CHOP-Bleo”) in advanced (non-Hodgkin) malignant lymphoma. Blood. 1977; 49: 325333.
  • 24
    Straus DJ, Wong GY, Liu J, et al. Small non-cleaved-cell lymphoma (undifferentiated lymphoma, Burkitt's type) in American adults: results with treatment designed for acute lymphoblastic leukemia. Am J Med. 1991; 90: 328337.
  • 25
    Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986; 104: 757765.
  • 26
    O'Brien JP. An economic analysis of the NHL-15 protocol for diffuse aggressive lymphomas: the potential for substantially reducing cost by improving outcomes [abstract]. Am Soc Hematol. 1997; 90: 249a.
  • 27
    McMaster ML, Greer JP, Greco FA, Johnson DH, Wolff SN, Hainsworth JD. Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. J Clin Oncol. 1991; 9: 941946.
  • 28
    Bernstein JI, Coleman CN, Strickler JG, Dorfman RF, Rosenberg SA. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol. 1986; 4: 847858.
  • 29
    Longo DL, Duffey PL, Jaffe ES, et al. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. J Clin Oncol. 1994; 12: 21532159.
  • 30
    Ziegler JL. Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience. N Engl J Med. 1977; 297: 7580.
  • 31
    Lopez TM, Hagemeister FB, McLaughlin P, et al. Small noncleaved cell lymphoma in adults: superior results for Stages I-III disease. J Clin Oncol. 1990; 8: 615622.
  • 32
    Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001; 19: 21712178.
  • 33
    Navarro JT, Ribera JM, Oriol A, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol. 2001; 112: 909915.
  • 34
    Gisselbrecht C, Oksenhendler E, Tirelli U, et al. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group. Am J Med. 1993; 95: 188196.
  • 35
    Oksenhendler E, Gerard L, Dubreuil ML, et al. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma. Leuk Lymphoma. 2000; 39: 8795.
  • 36
    Pluda JM, Venzon DJ, Tosato G, et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol. 1993; 11: 10991107.
  • 37
    International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000; 92: 18231830.
  • 38
    Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002; 94: 14921499.